Admedus: Solid 3QFY15 result
Morgans
Admedus (AHZ, Add, Price Target A$0.20) AHZ posted a solid 3QFY15 result with revenue up 47% to A$2.4m. We estimate the key CardiolCel® sales were approximately A$800,000 with now over 60 centres in US and Europe using the device. Following the recent capital raising, AHZ is well funded and a number of key catalysts over the coming quarters will likely see the share price recover from the current levels. Add maintained. Report attached
1 topic
1 stock mentioned
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise